Professor Janaki Amin

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, vol. 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025

Madhavi V; Wines BD; Amin J; Emery S; Lopez E; Kelleher A; Center RJ; Mark Hogarth P; Chung AW; Kent SJ, 2017, 'HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV', Journal of Virology, vol. 91, http://dx.doi.org/10.1128/JVI.00700-17

Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Mark Hogarth P; Reynaldi A; Davenport MP, 2017, 'Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption', Journal of Virology, vol. 91, http://dx.doi.org/10.1128/JVI.00603-17

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, vol. 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Madhavi V; Kulkarni A; Shete A; Lee WS; McLean MR; Kristensen AB; Ghate M; Wines BD; Hogarth PM; Parsons MS, 2017, 'Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts', Journal of Acquired Immune Deficiency Syndromes, vol. 75, pp. 345 - 353, http://dx.doi.org/10.1097/QAI.0000000000001380

Lau A; Kong F; Fairley CK; Donovan B; Chen M; Bradshaw C; Boyd M; Amin J; Timms P; Tabrizi S, 2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised co', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-016-2125-7

Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453

Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients wi', The Lancet HIV, vol. 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8

Teeraananchai S; Kerr SJ; Amin J; Ruxrungtham K; Law MG, 2017, 'Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis', HIV Medicine, vol. 18, pp. 256 - 266, http://dx.doi.org/10.1111/hiv.12421

Moore CL; Gidding HF; Jin F; Mao L; Petoumenos K; Zablotska IB; Poynten IM; Prestage G; Law MG; Grulich AE, 2016, 'Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men', AIDS and Behavior, vol. 20, pp. 2372 - 2386, http://dx.doi.org/10.1007/s10461-016-1303-3

Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, vol. 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, vol. 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010

Moore CL; Grulich AE; Prestage G; Gidding HF; Jin F; Petoumenos K; Zablotska IB; Poynten IM; Mao L; Law MG, 2016, 'Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men.', J Acquir Immune Defic Syndr, vol. 73, pp. 589 - 597, http://dx.doi.org/10.1097/QAI.0000000000001147

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus', Clinical Infectious Diseases, vol. 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207

Moore CL; Grulich AE; Prestage G; Gidding HF; Jin F; Petoumenos K; Zablotska IB; Poynten IM; Mao L; Law MG, 2016, 'Hospitalization for anxiety and mood disorders in HIV-infected and -uninfected gay and bisexual men', Journal of Acquired Immune Deficiency Syndromes, vol. 73, pp. 589 - 597, http://dx.doi.org/10.1097/QAI.0000000000001147

Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, vol. 13, http://dx.doi.org/10.1186/s12985-016-0482-x

Achhra AC; Mwasakifwa G; Amin J; Boyd MA, 2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, vol. 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7

Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, vol. 16, http://dx.doi.org/10.1186/s12879-016-1567-2

Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, vol. 18, pp. 69 - 80

Moore CL; Gidding HF; Law MG; Amin J, 2016, 'Poor record linkage sensitivity biased outcomes in a linked cohort analysis', Journal of Clinical Epidemiology, vol. 75, pp. 70 - 77, http://dx.doi.org/10.1016/j.jclinepi.2016.01.023

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A, 2016, 'Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study', Clinical Pharmacokinetics, vol. 55, pp. 861 - 873, http://dx.doi.org/10.1007/s40262-015-0360-5

Moore CL; Grulich AE; Prestage G; Gidding HF; Jin F; Mao L; Petoumenos K; Zablotska IB; Poynten IM; Law MG, 2016, 'Hospitalisation rates and associated factors in community-based cohorts of HIV-infected and -uninfected gay and bisexual men', HIV Medicine, vol. 17, pp. 327 - 339, http://dx.doi.org/10.1111/hiv.12312

Lee FJ; Amin J; Carr A, 2015, 'Limited reporting of major harms in studies of initial combination antiretroviral therapy: a systematic review', AIDS (London, England), vol. 29, pp. 921 - 929, http://dx.doi.org/10.1097/QAD.0000000000000633

Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK, 2015, 'Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels', AIDS (London, England), vol. 29, pp. 911 - 919, http://dx.doi.org/10.1097/QAD.0000000000000625

Swart A; Meagher NS; Van Leeuwen MT; Zhao K; Grulich A; Mao L; Randall DA; Degenhardt L; Burns L; O'Connell D, 2015, 'Examining the quality of name code record linkage: What is the impact on death and cancer risk estimates? A validation study', Australian and New Zealand Journal of Public Health, vol. 39, pp. 141 - 147, http://dx.doi.org/10.1111/1753-6405.12287

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS O', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0140623

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A, 2015, 'Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study', Clinical Pharmacology and Therapeutics, vol. 98, pp. 406 - 416, http://dx.doi.org/10.1002/cpt.156

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Lamoury FMJ; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J, 2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0131437

Vajdic CM; Marashi Pour S; Olivier J; Swart A; O'Connell DL; Falster MO; Meagher NS; Mao L; Grulich AE; Randall DA, 2015, 'Corrigendum to "The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study" [Drug Alcohol Depend. 152C (2015) 264-271] DOI', Drug and Alcohol Dependence, vol. 154, pp. 304, http://dx.doi.org/10.1016/j.drugalcdep.2015.06.024

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³ study', Journal of Viral Hepatitis, vol. 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Vajdic CM; Pour SM; Olivier J; Swart A; O'Connell DL; Falster MO; Meagher NS; Mao L; Grulich AE; Randall DA, 2015, 'The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study', Drug and Alcohol Dependence, vol. 152, pp. 264 - 271, http://dx.doi.org/10.1016/j.drugalcdep.2015.03.026

Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avinghsanon A; Chetchotisakd P, 2015, 'Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial', Clinical Infectious Diseases, vol. 60, pp. 1026 - 1032, http://dx.doi.org/10.1093/cid/ciu976

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC³ study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0122232

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H, 2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118228

Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H, 2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, vol. 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7

Larney S; Grebely J; Falster M; Swart A; Amin J; Degenhardt L; Burns L; Vajdic CM, 2015, 'Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study', Drug and Alcohol Dependence, vol. 148, pp. 213 - 216, http://dx.doi.org/10.1016/j.drugalcdep.2014.12.027

Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M, 2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, vol. 62, pp. 269 - 277, http://dx.doi.org/10.1016/j.jhep.2014.09.001

Luciani F; Bretaña NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), vol. 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 67, pp. 161 - 168, http://dx.doi.org/10.1097/QAI.0000000000000288

Amin J; Law MG; Puls R; Kelleher A; Cooper DA; Emery S, 2014, 'Comparison of central and local HIV-1 RNA quantification from two international clinical trials', AIDS, vol. 28, pp. 2480 - 2483, http://dx.doi.org/10.1097/QAD.0000000000000461

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³ Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Moore CL; Amin J; Gidding HF; Law MG, 2014, 'A new method for assessing how sensitivity and specificity of linkage studies affects estimation', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0103690

Luciani F; Bretaña NA; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction, http://dx.doi.org/10.1111/add.12643

Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J, 2014, 'Dynamics of HCV RNA levels during acute hepatitis C virus infection', Journal of Medical Virology, http://dx.doi.org/10.1002/jmv.24010

Muscatello DJ; Amin J; MacIntyre CR; Newall AT; Rawlinson WD; Sintchenko V; Gilmour R; Thackway S, 2014, 'Inaccurate ascertainment of morbidity and mortality due to influenza in administrative databases: A population-based record linkage study', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0098446

Lee FJ; Amin J; Carr A, 2014, 'Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: A systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0097482

Alavi M; Law MG; Grebely J; Thein HH; Walter S; Amin J; Dore GJ, 2014, 'Lower life expectancy among people with an HCV notification: A population-based linkage study', Journal of Viral Hepatitis, vol. 21, http://dx.doi.org/10.1111/jvh.12245

Haskelberg H; Cordery DV; Amin J; Kelleher AD; Cooper DA; Emery S, 2014, 'HLA Alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0093333

Haskelberg H; Pocock N; Amin J; Ebeling PR; Emery S; Carr A, 2014, 'Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0094858

ENCORE1 Study Group, 2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.', Lancet, vol. 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X

Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, vol. 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639

Deans GD; Raffa JD; Lai C; Fischer B; Krajden M; Amin J; Walter SR; Dore GJ; Grebely J; Tyndall MW, 2013, 'Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada.', CMAJ Open, vol. 1, pp. E68 - E76, http://dx.doi.org/10.9778/cmajo.20130002

Phetsouphanh C; Xu Y; Amin J; Seddiki N; Procopio F; Sekaly RP; Zaunders JJ; Kelleher AD, 2013, 'Characterization of Transcription Factor Phenotypes within Antigen-Specific CD4+ T Cells Using Qualitative Multiplex Single-Cell RT-PCR', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0074946

Rodger AJ; Lodwick R; Schechter M; Deeks S; Amin J; Gilson R; Paredes R; Bakowska E; Engsig FN; Phillips A, 2013, 'Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population', AIDS, vol. 27, pp. 973 - 979, http://dx.doi.org/10.1097/QAD.0b013e32835cae9c

Lee FJ; Amin J; Bloch M; Pett SL; Marriott D; Carr A, 2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', Journal of Acquired Immune Deficiency Syndromes, vol. 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578

Wren LH; Chung AW; Isitman G; Kelleher AD; Parsons MS; Amin J; Cooper DA; Stratov I; Navis M; Kent SJ, 2013, 'Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection', Immunology, vol. 138, pp. 116 - 123, http://dx.doi.org/10.1111/imm.12016

Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL, 2013, 'Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0061297

Mccredie L; Luciani F; Teutsch S; Amin J; Topp L; Dolan K; Lloyd A, 2012, 'BLOODY PRISONS: INCIDENCE OF RISK BEHAVIOURS AND HEPATITIS C VIRUS TRANSMISSION IN AN AUSTRALIAN PRISONER COHORT', DRUG AND ALCOHOL REVIEW, vol. 31, pp. 57 - 57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Achhra AC; Amin J, 2012, 'Race and CD4 ⁺ T-cell count in HIV prognosis and treatment', Future Virology, vol. 7, pp. 193 - 203, http://dx.doi.org/10.2217/fvl.11.143

Gidding HF; Law MG; Amin J; Ostapowicz G; Weltman M; Macdonald GA; Sasadeusz JJ; Haber PAW; George J; Dore GJ, 2012, 'Hepatitis C treatment outcomes in Australian clinics', Medical Journal of Australia, vol. 196, pp. 633 - 637, http://dx.doi.org/10.5694/mja12.10014

Thein HH; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2012, 'Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort', Hepatology Research, vol. 42, pp. 1175 - 1186, http://dx.doi.org/10.1111/j.1872-034X.2012.01037.x

Achhra AC; Amin J; Sabin C; Chu H; Dunn D; Kuller LH; Kovacs JA; Cooper DA; Emery S; Law MG, 2012, 'Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals', AIDS, vol. 26, pp. 1707 - 1717, http://dx.doi.org/10.1097/QAD.0b013e328355d659

Hsu DC; Zaunders JJ; Plit M; Leeman C; Ip S; Iampornsin T; Pett SL; Bailey M; Amin J; Ubolyam S, 2012, 'A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays', Tuberculosis, vol. 92, pp. 321 - 327, http://dx.doi.org/10.1016/j.tube.2012.03.008

Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; Allworth A; Anderson J; Baker D; Bloch M, 2012, 'Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0038377

Brown DA; Hance KW; Rogers CJ; Sansbury LB; Albert PS; Murphy G; Laiyemo AO; Wang Z; Cross AJ; Schatzkin A, 2012, 'Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): A potential screening tool for the prevention of colon cancer?', Cancer Epidemiology Biomarkers and Prevention, vol. 21, pp. 337 - 346, http://dx.doi.org/10.1158/1055-9965.EPI-11-0786

Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M, 2012, 'Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Cordery DV; Martin A; Amin J; Kelleher AD; Emery S; Cooper DA, 2012, 'The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV', AIDS, vol. 26, pp. 2337 - 2344, http://dx.doi.org/10.1097/QAD.0b013e32835ab213

Cordery DV; Humphries A; Amin J; Kelleher AD; Emery S; Cooper DA, 2011, 'The influence of HLA supertype on thymidine analogue induced body composition changes in STEAL', ANTIVIRAL THERAPY, vol. 16, pp. A20 - A21, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375900025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr A, 2011, 'Lower fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults', ANTIVIRAL THERAPY, vol. 16, pp. A6 - A7, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375900007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Kumarasinghe G; Herrera C; Stuart S; Victor A; Amin J; Hayward C; MacDonald P; Danta M, 2011, 'Noninvasive assessment of liver fibrosis in cardiac disease', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 26, pp. 54 - 54, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295157300141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Achhra AC; Phanuphak P; Amin J, 2011, 'Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries', Current Opinion in HIV and AIDS, vol. 6, pp. 258 - 265, http://dx.doi.org/10.1097/COH.0b013e3283476c72

Chung AW; Navis M; Isitman G; Wren L; Silvers J; Amin J; Kent SJ; Stratov I, 2011, 'Activation of NK cells by ADCC antibodies and HIV disease progression', Journal of Acquired Immune Deficiency Syndromes, vol. 58, pp. 127 - 131, http://dx.doi.org/10.1097/QAI.0b013e31822c62b9

Gidding HF; Dore GJ; Amin J; Law MG, 2011, 'Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: A population-based linkage study', BMC Public Health, vol. 11, http://dx.doi.org/10.1186/1471-2458-11-52

Gidding HF; Law MG; Amin J; MacDonald GA; Sasadeusz JJ; Jones TL; Strasser SI; George J; Dore GJ, 2011, 'Predictors of deferral of treatment for hepatitis C infection in Australian clinics', Medical Journal of Australia, vol. 194, pp. 398 - 402

Walter SR; Thein HH; Amin J; Gidding HF; Ward K; Law MG; George J; Dore GJ, 2011, 'Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006', Journal of Hepatology, vol. 54, pp. 879 - 886, http://dx.doi.org/10.1016/j.jhep.2010.08.035

Thein HH; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2011, 'Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: A population-based cohort study, 1992-2007', Journal of Viral Hepatitis, vol. 18, http://dx.doi.org/10.1111/j.1365-2893.2011.01440.x

Gidding HF; Amin J; Dore GJ; Law MG, 2011, 'Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C', Epidemiology and Infection, vol. 139, pp. 1151 - 1158, http://dx.doi.org/10.1017/S095026881000258X

Walter SR; Thein HH; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2011, 'Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C', Journal of Gastroenterology and Hepatology (Australia), vol. 26, pp. 1757 - 1764, http://dx.doi.org/10.1111/j.1440-1746.2011.06785.x

Jackson A; Hill A; Puls R; Else L; Amin J; Back D; Lin E; Khoo S; Emery S; Morley R, 2011, 'Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers', Journal of Antimicrobial Chemotherapy, vol. 66, pp. 635 - 640, http://dx.doi.org/10.1093/jac/dkq468

Byakwaga H; Kelly M; Purcell DFJ; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA, 2011, 'Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 ⁺ T-cell response: A randomized controlle', Journal of Infectious Diseases, vol. 204, pp. 1532 - 1540, http://dx.doi.org/10.1093/infdis/jir559

Kariminia A; Chokephaibulkit K; Pang J; Lumbiganon P; Hansudewechakul R; Amin J; Kumarasamy N; Puthanakit T; Kurniati N; Nik Yusoff NK, 2011, 'Cohort profile: The TREAT Asia pediatric HIV observational database', International Journal of Epidemiology, vol. 40, pp. 15 - 24, http://dx.doi.org/10.1093/ije/dyp358

Achhra AC; Zhou J; Choi JY; Hoy J; Zhang F; Templeton DJ; Merati T; Woolley I; Petoumenos K; Amin J, 2011, 'The clinical significance of CD4 counts in asian and caucasian HIV-infected populations: Results from TAHOD and AHOD', Journal of the International Association of Physicians in AIDS Care, vol. 10, pp. 160 - 170, http://dx.doi.org/10.1177/1545109711402213

Martin A; Amin J; Emery S; Baker D; Carr A; Cooper DA; Bloch M, 2011, 'Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or Abacavir-Lamivudine', PLoS ONE, vol. 6, http://dx.doi.org/10.1371/journal.pone.0026885

Danta M; Kumarasinghe G; Stuart S; Victor A; Amin J; Hayward C; Macdonald P, 2010, 'Liver elastography in cardiac disease (LECD) study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 25, pp. A24 - A25, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000283321200064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Carey D; Amin J; Boyd M; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials', Journal of Antimicrobial Chemotherapy, vol. 65, pp. 1878 - 1888, http://dx.doi.org/10.1093/jac/dkq231

Salmon AM; Van Beek I; Amin J; Kaldor J; Maher L, 2010, 'The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia', Addiction, vol. 105, pp. 676 - 683, http://dx.doi.org/10.1111/j.1360-0443.2009.02837.x

Van Leeuwen MT; Webster AC; McCredie MRE; Stewart JH; McDonald SP; Amin J; Kaldor JM; Chapman JR; Vajdic C; Grulich AE, 2010, 'Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: Population based retrospective cohort study', BMJ (Online), vol. 340, pp. 463, http://dx.doi.org/10.1136/bmj.c570

Gidding HF; Amin J; Dore GJ; Ward K; Law MG, 2010, 'Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia', Journal of Hepatology, vol. 53, pp. 43 - 49, http://dx.doi.org/10.1016/j.jhep.2010.01.036

Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR, 2010, 'Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Achhra AC; Amin J; Law MG; Emery S; Gerstoft J; Gordin FM; Vjecha MJ; Neaton JD; Cooper DA, 2010, 'Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients', AIDS, vol. 24, pp. 1877 - 1886, http://dx.doi.org/10.1097/QAD.0b013e32833b1b26

Cordery DV; Hesse K; Amin J; Cooper DA, 2010, 'Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients', Antiviral Therapy, vol. 15, pp. 1035 - 1038, http://dx.doi.org/10.3851/IMP1647

Zheng H; Ehrlich F; Amin J, 2010, 'Productivity loss resulting from coronary heart disease in Australia', Applied Health Economics and Health Policy, vol. 8, pp. 179 - 189, http://dx.doi.org/10.2165/11530520-000000000-00000

Zheng H; Ehrlich F; Amin J, 2010, 'Economic evaluation of the direct healthcare cost savings resulting from the use of walking interventions to prevent coronary heart disease in Australia', International Journal of Health Care Finance and Economics, vol. 10, pp. 187 - 201, http://dx.doi.org/10.1007/s10754-009-9074-2

Yan CS; Hanafi I; Kelleher AD; Carr AD; Amin J; McNally LP; Cunningham PH, 2010, 'Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification', Journal of Clinical Virology, vol. 49, pp. 249 - 253, http://dx.doi.org/10.1016/j.jcv.2010.08.016

Amin J; Martin A; Bloch M; Carr A, 2010, 'Reply to Landman and Soonawala', Clinical Infectious Diseases, vol. 50, pp. 1200 - 1201, http://dx.doi.org/10.1086/651469

Martin A; Amin J; Cooper DA; Carr A; Kelleher AD; Bloch M; Baker D; Woolley I; Emery S, 2010, 'Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: A randomized clinical trial', AIDS, vol. 24, pp. 2657 - 2663, http://dx.doi.org/10.1097/QAD.0b013e32833f147f

Amin J; De Lazzari E; Emery S; Martin A; Martinez E; Carr A; Gatell J; Cooper DA, 2010, 'Simplification with fixed-dose Tenofovir-Emtricitabine or Abacavir-Lamivudine in treatment experienced, virologically suppressed adults with Hiv infection: Combined analysis of two randomised, non-inf', Journal of AIDS and Clinical Research, vol. 1, pp. 2 - 5, http://dx.doi.org/10.4172/2155-6113.1000103

Zheng H; Ehrlich F; Amin J, 2010, 'Quantifying the effect size of walking interventions to reduce the risk of coronary heart disease: Meta-analysis', International Journal of Body Composition Research, vol. 8, pp. S51 - S59, http://www.ijbcr.com/IJBCR_8_Supplement.pdf

Carr A; Amin J, 2009, 'Efficacy and tolerability of initial antiretroviral therapy: A systematic review', AIDS, vol. 23, pp. 343 - 353, http://dx.doi.org/10.1097/QAD.0b013e32831db232

Nguyen VT; Amin J; Law MG; Dore GJ, 2009, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia', Journal of Gastroenterology and Hepatology (Australia), vol. 24, pp. 436 - 442, http://dx.doi.org/10.1111/j.1440-1746.2008.05577.x

Alcantara S; Reece J; Amarasena T; De Rose R; Manitta J; Amin J; Kent SJ, 2009, 'Thrombocytopenia is strongly associated with simian AIDS in pigtail macaques', Journal of Acquired Immune Deficiency Syndromes, vol. 51, pp. 374 - 379, http://dx.doi.org/10.1097/QAI.0b013e3181a9cbcf

Salmon AM; Van Beek I; Amin J; Grulich A; Maher L, 2009, 'High HIV testing and low HIV prevalence among injecting drug users attending the Sydney Medically Supervised Injecting Centre', Australian and New Zealand Journal of Public Health, vol. 33, pp. 280 - 283, http://dx.doi.org/10.1111/j.1753-6405.2009.00389.x

Van Leeuwen MT; Grulich AE; McDonald SP; McCredie MRE; Amin J; Stewart JH; Webster AC; Chapman JR; Vajdic CM, 2009, 'Immunosuppression and other risk factors for lip cancer after kidney transplantation', Cancer Epidemiology Biomarkers and Prevention, vol. 18, pp. 561 - 569, http://dx.doi.org/10.1158/1055-9965.EPI-08-0919

Vajdic CM; Van Leeuwen MT; Webster AC; McCredie MRE; Stewart JH; Chapman JR; Amin J; McDonald SP; Grulich AE, 2009, 'Cutaneous melanoma is related to immune suppression in kidney transplant recipients', Cancer Epidemiology Biomarkers and Prevention, vol. 18, pp. 2297 - 2303, http://dx.doi.org/10.1158/1055-9965.EPI-09-0278

Stewart JH; Vajdic CM; Van Leeuwen MT; Amin J; Webster AC; Chapman JR; McDonald SP; Grulich AE; McCredie MRE, 2009, 'The pattern of excess cancer in dialysis and transplantation', Nephrology Dialysis Transplantation, vol. 24, pp. 3225 - 3231, http://dx.doi.org/10.1093/ndt/gfp331

Van Leeuwen MT; Grulich AE; Webster AC; McCredie MRE; Stewart JH; McDonald SP; Amin J; Kaldor JM; Chapman JR; Vajdic CM, 2009, 'Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation', Blood, vol. 114, pp. 630 - 637, http://dx.doi.org/10.1182/blood-2009-02-202507

Razali K; Amin J; Dore GJ; Law MG, 2009, 'Modelling and calibration of the hepatitis C epidemic in Australia', Statistical Methods in Medical Research, vol. 18, pp. 253 - 270, http://dx.doi.org/10.1177/0962280208094689

Zheng H; Orsini N; Amin J; Wolk A; Nguyen VTT; Ehrlich F, 2009, 'Quantifying the dose-response of walking in reducing coronary heart disease risk: Meta-analysis', European Journal of Epidemiology, vol. 24, pp. 181 - 192, http://dx.doi.org/10.1007/s10654-009-9328-9

Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A, 2009, 'Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial', Clinical Infectious Diseases, vol. 49, pp. 1591 - 1601, http://dx.doi.org/10.1086/644769

Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand', Hepatology, vol. 48, pp. 1062 - 1069, http://dx.doi.org/10.1002/hep.22462

Nguyen VTT; Razali K; Amin J; Law MG; Dore GJ, 2008, 'Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries', Journal of Gastroenterology and Hepatology (Australia), vol. 23, pp. 922 - 929, http://dx.doi.org/10.1111/j.1440-1746.2007.05065.x

Macdonald V; Dore GJ; Amin J; Van Beek I, 2007, 'Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre', Sexual Health, vol. 4, pp. 27 - 30, http://dx.doi.org/10.1071/SH06008

Amin J; Law MG, 2007, 'Causes of death in hepatitis B and C: a methodological issue', Lancet, vol. 370, pp. 1033, http://dx.doi.org/10.1016/S0140-6736(07)61473-1

Amin J; O'Connell D; Bartlett M; Tracey E; Kaldor J; Law M; Dore G, 2007, 'Liver cancer and hepatitis B and C in New South Wales, 1990-2002: A linkage study', Australian and New Zealand Journal of Public Health, vol. 31, pp. 475 - 482, http://dx.doi.org/10.1111/j.1753-6405.2007.00121.x

Amin J; Law MG; Micallef J; Jauncey M; Van Beek I; Kaldor JM; Dore GJ, 2007, 'Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users', Epidemiology and Infection, vol. 135, pp. 144 - 150, http://dx.doi.org/10.1017/S0950268806006388

Micallef JM; Macdonald V; Jauncey M; Amin J; Rawlinson W; Van Beek I; Kaldor JM; White PA; Dore GJ, 2007, 'High incidence of hepatitis C virus reinfection within a cohort of injecting drug users', Journal of Viral Hepatitis, vol. 14, pp. 413 - 418, http://dx.doi.org/10.1111/j.1365-2893.2006.00812.x

Hamlyn E; McAllister J; Winston A; Sinclair B; Amin J; Carr A; Cooper DA, 2006, 'Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?', Sexually Transmitted Infections, vol. 82, pp. 21 - 23, http://dx.doi.org/10.1136/sti.2005.014662

Amin J; Law MG; Dore G, 2006, 'Mortality in patients with hepatitis B or hepatitis C - Authors' reply', Lancet, vol. 368, pp. 1767, http://dx.doi.org/10.1016/S0140-6736(06)69729-8

Amin J; Dore GJ; O'Connell DL; Bartlett M; Tracey E; Kaldor JM; Law MG, 2006, 'Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study', Journal of Hepatology, vol. 45, pp. 197 - 203, http://dx.doi.org/10.1016/j.jhep.2006.02.014

Amin J; Law MG; Bartlett M; Kaldor JM; Dore GJ, 2006, 'Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study', Lancet, vol. 368, pp. 938 - 945, http://dx.doi.org/10.1016/S0140-6736(06)69374-4

Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM, 2006, 'Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis', Clinical Cancer Research, vol. 12, pp. 89 - 96, http://dx.doi.org/10.1158/1078-0432.CCR-05-1331

Winston A; Amin J; Mallon PWG; Marriott D; Carr A; Cooper DA; Emery S, 2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, vol. 7, pp. 105 - 111, http://dx.doi.org/10.1111/j.1468-1293.2006.00349.x

Winston A; Amin J; Hales G; Cooper DA; Emery S, 2006, 'Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced hiv-positive individuals', AIDS Research and Human Retroviruses, vol. 22, pp. 338 - 341, http://dx.doi.org/10.1089/aid.2006.22.338

Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J; Emery S, 2006, 'Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study', Antiviral Therapy, vol. 11, pp. 409 - 419

Amin J; Law MG; O'Connell D; Bartlett M; Tracey E; Kaldor JM; Dore GJ, 2005, 'Cancer incidence in people with hepatitis B or C infection: A population based cohort study', JOURNAL OF HEPATOLOGY, vol. 42, pp. 88 - 88, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000229024000228&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Hallinan R; Byrne A; Amin J; Dore GJ, 2005, 'Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy', Journal of Gastroenterology and Hepatology (Australia), vol. 20, pp. 1082 - 1086, http://dx.doi.org/10.1111/j.1440-1746.2005.03882.x

Grulich AE; Cunningham P; Munier ML; Prestage G; Amin J; Ringland C; Whitby D; Kippax S; Kaldor JM; Rawlinson W, 2005, 'Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia', Sexual Health, vol. 2, pp. 13 - 18, http://dx.doi.org/10.1071/SH04029

Winston A; McAllister J; Amin J; Cooper DA; Carr A, 2005, 'The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis', HIV Medicine, vol. 6, pp. 191 - 197, http://dx.doi.org/10.1111/j.1468-1293.2005.00288.x

Winston A; Bloch M; Carr A; Amin J; Mallon PWG; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, vol. 56, pp. 380 - 387, http://dx.doi.org/10.1093/jac/dki235

Winston A; Hales G; Amin J; Van Schaick E; Cooper DA; Emery S, 2005, 'The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals', AIDS, vol. 19, pp. 1393 - 1399, http://dx.doi.org/10.1097/01.aids.0000181009.77632.36

Hallinan R; Byrne A; Amin J; Dore GJ, 2004, 'Hepatitis C virus incidence among injecting drug users on opioid replacement therapy', Australian and New Zealand Journal of Public Health, vol. 28, pp. 576 - 578, http://dx.doi.org/10.1111/j.1467-842X.2004.tb00050.x

Jauncey M; Micallef JM; Gilmour S; Amin J; White PA; Rawlinson W; Kaldor JM; Van Beek I; Dore GJ, 2004, 'Clearance of hepatitis C virus after newly acquired infection in injection drug users', Journal of Infectious Diseases, vol. 190, pp. 1270 - 1274, http://dx.doi.org/10.1086/423943

Moyle G; Sawyer W; Law M; Amin J; Hill A, 2004, 'Changes in Hematologic Parameters and Efficacy of Thymidine Analogue - Based, Highly Active Antiretroviral Therapy: A Meta-Analysis of Six Prospective, Randomized, Comparative Studies', Clinical Therapeutics, vol. 26, pp. 92 - 97, http://dx.doi.org/10.1016/S0149-2918(04)90009-4

Amin J; Kaye M; Skidmore S; Pillay D; Cooper DA; Dore GJ, 2004, 'HIV and hepatitis C coinfection within the CAESAR study', HIV Medicine, vol. 5, pp. 174 - 179, http://dx.doi.org/10.1111/j.1468-1293.2004.00207.x

Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J, 2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study', AIDS, vol. 18, pp. 1029 - 1036, http://dx.doi.org/10.1097/00002030-200404300-00011

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA; Kotsiou G; Norrito L; Dwyer D, 2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection:', HIV Clinical Trials, vol. 4, pp. 252 - 261, http://dx.doi.org/10.1310/K2U9-QC2V-1Y3V-5DYF

Mikhailof N; Carr A; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy [1] (multiple letters)', Journal of the American Medical Association, vol. 288, pp. 1716

French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1', HIV Clinical Trials, vol. 3, pp. 177 - 185, http://dx.doi.org/10.1310/9N21-1HG1-7N1Q-JKW1

Carr A; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy - Reply', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 288, pp. 1716 - 1716, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178484700016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M, 2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial', Journal of the American Medical Association, vol. 288, pp. 207 - 215, http://dx.doi.org/10.1001/jama.288.2.207

Miller J; Brown D; Amin J; Kent-Hughes J; Law M; Kaldor J; Cooper DA; Carr A, 2002, 'A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, vol. 16, pp. 2195 - 2200, http://dx.doi.org/10.1097/00002030-200211080-00012

Carr AD; Workman C; Smith DE; Hoy JF; Doong N; Amin J; Law MG; Cooper DA, 2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, vol. 288, pp. 207 - 215

Amin J; Gilbert GL; Escott RG; Heath TC; Burgess MA, 2001, 'Hepatitis A epidemiology in Australia: National seroprevalence and notifications', Medical Journal of Australia, vol. 174, pp. 338 - 341

Amin J; McIntyre P; Gidding H; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998', Communicable Diseases Intelligence Quarterly Report

McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Commun Dis Intell, vol. Suppl, pp. v - 83, https://www.ncbi.nlm.nih.gov/pubmed/12049363

Gidding HF; Amin J; McIntyre PB, 2000, 'Notifications of vaccine preventable diseases in Australia. Quarterly report (January-March 2000).', Communicable diseases intelligence, vol. 24, pp. 239 - 241

McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable diseases intelligence, vol. Suppl

McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable diseases intelligence, vol. 24, pp. 276 - 277

Amin J; Wong M, 1999, 'Measles-mumps-rubella immunisation, autism and inflammatory bowel disease: update', Communicable Diseases Intelligence Quarterly Report

Thomson J; Lin M; Halliday L; Preston G; McIntyre P; Gidding H; Amin J; Roberts L; Higgins K; Brooke F, 1999, 'Australia's notifiable diseases status, 1998. Annual report of the National Notifiable Diseases Surveillance System.', Communicable diseases intelligence, vol. 23, pp. 277 - 305

Amin J; Hueston L; Dwyer DE; Capon A, 1998, 'Ross River virus infection in the north-west outskirts of the Sydney basin', Communicable Diseases Intelligence Quarterly Report, vol. 22, pp. 101 - 102

Hajarizadeh B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J, 2013, 'EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, pp. S470 - S471, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, NETHERLANDS, 24 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)61158-7

Ebeling PR; Haskelberg H; Hoy J; Amin J; Emery S; Carr A, 2011, 'LOWER FAT MASS AND LOWER BONE FORMATION PREDICT GREATER BONE LOSS WITH TENOFOVIR IN HIV-INFECTED ADULTS', in OSTEOPOROSIS INTERNATIONAL, SPRINGER LONDON LTD, Gold Coast, AUSTRALIA, pp. S614 - S615, presented at IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, Gold Coast, AUSTRALIA, 04 - 08 September 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000309258200234&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Danta M; Kumarasinghe G; Victor A; Stuart SE; Amin J; Hayward CS; Macdonald PS, 2010, 'LIVER ELASTOGRAPHY IN CARDIAC DISEASE (LECD) STUDY', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, pp. 961A - 961A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 29 October - 02 November 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775601658&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Puls RL; Brown D; Fahey P; Amin J; Breit S; Carr A, 2010, 'Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, London, ENGLAND, pp. A28 - A29, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, ENGLAND, 04 - 06 November 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Puls RL; Brown D; Fahey P; Amin J; Breit S; Carr A, 2010, 'Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, London, ENGLAND, pp. A28 - A29, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, ENGLAND, 04 - 06 November 2010, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Carey D; Amin J; Emery S, 2009, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir in randomized trials: systematic review and meta-analysis', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Philadelphia, PA, pp. A58 - A58, presented at 11th International Workshop on AdverseDrug Reactions and Co-Morbidities in HIV, Philadelphia, PA, 26 - 28 October 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272060000079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Nguyen VTT; Amin J; Law MG; Dore GJ, 2008, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A343 - A343, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2006, 'Estimates of Hepatitis B-Realted Liver Cancer Among Vietnam Born Population in Australia', in 18th Annual ASHM Conference, 18th Annual ASHM Conference, Melbourne, pp. 152 - 153, presented at 18th Annual ASHM Conference, Melbourne, 11 - 14 October 2006

Amin J; Carr A; Hill A; Emery S; Law M; Cooper DA, 2002, 'Haematological changes in patients randomized to HAART regimens containing either zidovudine or stavudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, SAN DIEGO, CALIFORNIA, pp. L60 - L60, presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, SAN DIEGO, CALIFORNIA, 22 - 25 September 2002, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179501500101&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 22 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3

Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, http://dx.doi.org/10.1111/jvh.12384

Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, Vol. 60, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Micallef JM; Jauncey M; Amin J; Rawlinson W; Gilmour S; van Beek I; Kaldor JM; White PA; Dore GJ, 2003, 'Hepatitis C virus reinfection within a cohort of injecting drug users.', in HEPATOLOGY, W B SAUNDERS CO, BOSTON, MASSACHUSETTS, Vol. 38, pp. 266A - 266A, presented at 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, BOSTON, MASSACHUSETTS, 24 - 28 October 2003, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000185816700230&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a